The prerequisite of atherosclerosis, endothelial dysfunction, is characterised by impaired endotheliumdependent vasodilation caused by the reduced bioavailibility of nitric oxide (NO). In order to assess the role of acute ACE inhibition in this setting, coronary arterial endothelial function was quantified following acute intracoronary administration of the angiotensinconverting enzyme (ACE) inhibitor quinapril.
Introduction
Endothelium-dependent vasodilation is impaired in patients with coronary heart disease and even in those with coronary risk factors without angiographically visible vascular damage. 1, 2 It is commonly accompanied by reduced bioavailibility of nitric oxide owing to elevated superoxide production in the vessel wall. [3] [4] [5] [6] [7] There is accumulating evidence that the renin-angiotensin-aldosterone system (RAAS) plays a central role in the development and progression of endothelial dysfunction. First, angiotensin II governs the release of reactive oxygen species via AT 1 -receptor activation. 8 Secondly, inhibition of ACE improves endothelial dysfunction in animals as well as in humans. [9] [10] [11] [12] [13] Finally, endothelial dysfunction is thought to be a potent predictor for the deleterious outcome of patients suffering from vascular damage. 14 In this context, a recent study confirmed that ACE inhibition greatly reduces the mortality of patients with coronary heart disease or major coronary risk factors. 15 ACE inhibitors diminish the production of angiotensin II, leading to reduced AT 1 -receptor activation and therefore to decreased superoxide levels in the vasculature. 8 Additionally, ACE inhibitors compromise the degradation of bradykinin, allowing increased stimulation of the bradykinin B 2 receptor and resulting in enhanced release of nitric oxide. 9 Both mechanisms seem to participate in the beneficial vascular effects of these drugs.
The following unanswered questions have evolved from our current knowledge. First, does ACE inhibition acutely affect coronary endothelial function? Secondly, what is the role of AT 1 -receptor antagonism in coronary endothelial-dependent vasodilation? Thirdly, are there synergistic effects between ACE inhibitors and AT 1 -receptor antagonists in this regard? In order to gain insight into these remaining uncertainties, we investigated coronary endothelial-dependent vasorelaxation after acute ACE inhibition, with or without concomitant AT 1 -receptor antagonism.
Methods
The study included 21 individuals with coronary risk factors such as hypercholesterolaemia, hypertension or smoking and a history of angina pectoris. Only patients without limiting coronary artery disease (diameter reduction less than 60% on quantitative coronary angiography) were recruited. Detailed data of these patients are shown in Table 1 . Patients were investigated after informed consent to measure coronary endothelial dysfunction. Nine patients received losartan, 50 mg, 12 hours and 1 hour, respectively, prior to the investigation.
After fasting overnight and cessation of any medication for 24 hours, 10.000 IU heparin and 500 mg acetylsalicylic acid were given intravenously. A 8F guiding catheter was introduced into the left main coronary artery. A perfusion catheter (Tracker 18 ® , 2.5 F, Target Therapeutics / Venture II ® , 2.1 F, Meditech) was installed over a Doppler guiding-wire (Flowire ® , Cardiometrics Inc.) and positioned 8-12 mm proximally to the sample volume of the Doppler wire which was located in a straight, non-branching region of the left anterior descending or left circumflex coronary artery. This allowed measurement of varia-tions of coronary microvascular resistance and macrovascular diameter changes under direct influence of the given substances, as well as reaction of macrovascular vessels to variations in blood flow.This procedure allowed selective infusion into a single coronary artery and enabled contrast application without discontinuation of infusion. Stability of the position of the system was documented by repeated coronary angiographies and flow velocity measurements before and after deep breathing. Following a 15 minutes equilibration period, resting measurements were taken (flow-velocity and quantitative angiography, 5 ml Iomeprol (Imeron ® , Bracco-Byk-Gulden, Konstanz, Germany). After two measurements under resting conditions, which did not differ by more than 10% in coronary diameter and flow velocity, intracoronary infusion of acetylcholine (Acetylcholinum ophtalmicum ® , CIBA-Vision Ophtalmics GmbH) via the perfusion catheter was started, using stepwise increasing doses, ranging from 0.1 to 10 µmol/l effective intracoronary concentration at an infusion rate of 1.3 ml/minute for 4 minutes each. During continuous infusion of acetylcholine, flow measurements were recorded, followed by coronary angiography. After 5 minutes, measurements were repeated and intracoronary infusion of adenosine (4 minutes 10 µmol/l, 1.3 ml/min, Adrekar ® , Sanofi Winthrop GmbH) was started. Resting state measurement was performed 5 minutes after termination of adenosine and before the intracoronary application of quinapril (10 mg/10 ml intracoronary infusion over 8 minutes, Gödecke Parke-Davis, Freiburg). Another measurement was performed 1 minute after quinapril application. The acetylcholine / adenosine infusion protocol was then repeated. Coronary flow index was calculated by multiplying the peak coronary flow velocity with the coronary artery cross-sectional diameter at the sample volume of the Doppler catheter.
The study protocol was approved by the institutional ethics review board of the University of Cologne. Statistics were performed using the SPSS ® Program package (Statistical Package for the Social Sciences). All tests were two-tailed, a p-value of 0.05 was considered significant. The results are shown as mean ± SEM.
Results
Twenty-one patients participated, of whom nine received losartan pre-treatment. Reproducibility of flow-measurement and quantitative coronary Microvascular endothelial dysfunction, defined as a drop in flow index under at least one concentration of acetylcholine or no increase of flow index above 10% of resting flow index, was observed in 9 of 12 (75%) patients not pre-treated with losartan. Acute administration of 10 mg quinapril improved macrovascular, as well as microvascular, endothelial function ( Figure 1) . However, only the enhancement of macrovascular dilation reached statistical significance.
Pre-treatment with the AT 1 -receptor antagonist losartan led to increased microvascular relaxation ( Figure 2 ), resulting in a significantly decreased frequency of microvascular endothelial dysfunction (2 of 9, 22% vs. 9 of 12, 75%; p<0.05). Macrovascular vasomotion was comparable between patients with or without losartan pretreatment ( Figure 2 ). Multivariate analysis showed no difference in endothelial dysfunction between patients with or without hypercholesterolaemia, arterial hypertension, or smoking. In patients pretreated with losartan, quinapril did not significantly change microvascular endothelial function, although there was a trend towards reduced endothelium-dependent vasodilatation after quinapril. Macrovascular vasomotion in patients with losartan pre-treatment was identical before and after quinapril (Figure 3 ).
Adenosine-induced vasodilation was similar between all groups tested (data not shown).

Discussion
Endothelial dysfunction is a primary event in atherogenesis. 1, 2 It is associated with coronary risk factors even before coronary heart disease is angiographically detected. [3] [4] [5] [6] [7] Moreover, endothelial dysfunction serves as potent predictor for the incidence of coronary events, warranting effective treatment regimens to prevent or improve this index of vascular damage. 14 ACE inhibitors exert favourable effects on endothelium-dependent vasorelaxation, as demonstrated by various animal studies and by intervention trials in patients with coronary heart disease. [9] [10] [11] [12] [13] Mechanistically, reduced AT 1 -receptor activation, as well as inhibited bradykinin degradation, underlie this phenomenon. 9 These findings were assessed after long-term ACE inhibition and therefore the question of whether the beneficial effects of ACE inhibitors would also occur acutely, remained uncertain.
This hypothesis was tested in patients with non-limiting coronary lesions depicting microand macrovascular impairment of vasorelaxation. Indeed, quinapril, an ACE inhibitor with high affinity for tissue ACE, 16 induced a notable improvement of micro-and macrovascular endothelial dysfunction, converting vasoconstriction during acetylcholine into vasodilatation.The fact that the increase of microvascular endothelial function did not reach statistical significance may be due to the limited numbers of patients investigated. However, the data reveal a clear tendency of enhanced microvascular vasorelaxation.The acute response to ACE inhibition may imply the importance of rapid reduction of local angiotensin II levels and thereby reduced superoxide production with respect to endothelial function. On the other hand, improved endothelial function could be based on prolonged action of locally produced bradykinin with concomitant nitric oxide release. These data suggest that modulation of vascular function may be possible within minutes and may not be dependent on long-term therapy, which may have implications for the treatment of patients with symptoms of acute coronary heart disease.
In any event, from these results it is not conclusible whether it is the angiotensin II-inhibiting or the bradykinin-enhancing features of ACE inhibitors that lead to the observed favourable effects. Therefore, pre-treatment with the AT 1receptor antagonist losartan was investigated. Following oral AT 1 -receptor antagonist treatment for 12 hours, macrovascular endothelial function did not differ significantly from that of patients without losartan pre-treatment. In contrast, there was a tendency towards an improvement of microvascular vasodilation. One could speculate that microvascular endothelial function is decisively influenced by AT 1 -receptor activation and free radical release, which could explain the benefical effect of losartan.Alternatively, macrovascular endothelial function may be influenced by long-term blockade of the AT 1 -receptor superoxide pathway or may be exclusively dependent on nitric oxide release via stimulation of the bradykinin B 2 receptor.According to our data, the latter possibility seems more convincing, since acute ACE inhibition improved macrovascular endothelial function.
Interestingly, pre-treatment with losartan diminished the favourable effects of quinapril on microas well as macrovascular function. The underlying mechanisms remain unresolved. It may be speculated that angiotensin II predominantly stimulates AT 2receptors during AT 1 -receptor blockade, thereby inducing bradykinin production. [17] [18] [19] It has been previously established that the bradykinin B 2 receptor is down-regulated upon activation by bradykinin. 20 Therefore, it may be assumed that pre-treatment with losartan leads, via AT 1 -receptor-induced bradykinin release, to down-regulation of the bradykinin B 2 receptor in the vasculature.This could then reduce the acute effects of quinapril. From the limited data presented in this study, this conclusion can not be reached with certainty. Further larger studies are required in order to clarify the role of AT 1receptor antagonism and its combination with ACE inhibition on coronary vascular function.
In patients with a high prevalence of macrovascular coronary endothelial dysfunction, the acute administration of quinapril improves endothelial function. Pre-treatment with an AT 1 -receptor antagonist reduces the prevalence of microvascular endothelial dysfunction but prevents the acute beneficial effects of ACE inhibition on endothelial dysfunction.Acute quinapril therapy may be a considerable treatment strategy for clinical syndromes with endothelial dysfunction, whereas AT 1 -receptor antagonism, as well as the combination of ACE inhibitors and AT 1 -receptor antagonists, requires further investigation before definitive conclusions may be made.
